|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 70.35 HKD | -2.22% |
|
+10.27% | +23.31% |
| Feb. 12 | Henlius Biotech Get China Nod for Trial Application of Multiple Myeloma Drug | MT |
| Feb. 11 | Henlius Biotech Doses First Patient in Colorectal Cancer Drug Trial | MT |
| Capitalization | 33.79B 38.23B 4.89B 4.12B 3.76B 3.59B 6.66B 443B 6.92B 43.72B 17.36B 214B 18.34B 17.96B 748B | P/E ratio 2025 * |
36.3x | P/E ratio 2026 * | 51.6x |
|---|---|---|---|---|---|
| Enterprise value | 36.93B 41.79B 5.35B 4.5B 4.11B 3.92B 7.28B 484B 7.56B 47.78B 18.97B 234B 20.05B 19.63B 817B | EV / Sales 2025 * |
6.23x | EV / Sales 2026 * | 5.42x |
| Free-Float |
14.64% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Shanghai Henlius Biotech, Inc.
| 1 day | -2.22% | ||
| 1 week | +10.27% | ||
| Current month | +22.77% | ||
| 1 month | +2.33% | ||
| 3 months | +8.65% | ||
| 6 months | -8.52% | ||
| Current year | +23.31% |
| 1 week | 63.85 |  | 74.5 |
| 1 month | 53.05 | | 74.5 |
| Current year | 53.05 | | 74.5 |
| 1 year | 20.15 | | 92 |
| 3 years | 9.6 | | 92 |
| 5 years | 9.6 | | 92 |
| 10 years | 9.6 | | 92 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jun Zhu
CEO | Chief Executive Officer | 48 | 2023-07-16 |
Wei Dong Jiang
CTO | Chief Tech/Sci/R&D Officer | - | 2009-11-30 |
Wei Huang
PSD | President | 58 | 2023-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Qi Yu Chen
CHM | Chairman | 53 | 2018-11-30 |
Xiao Hui Guan
BRD | Director/Board Member | 54 | 2018-12-23 |
Rui Lin Song
BRD | Director/Board Member | 63 | 2019-09-01 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.22% | +10.27% | +236.60% | +407.58% | 4.89B | |
| +2.49% | +2.25% | +19.24% | +6.49% | 82.42B | |
| +2.12% | +6.68% | +49.35% | +256.78% | 63.02B | |
| -0.52% | +71.00% | +71.00% | +71.00% | 54.86B | |
| -1.43% | -16.89% | -41.61% | -51.26% | 51.1B | |
| +0.52% | -2.32% | +43.10% | -32.02% | 28.84B | |
| +0.35% | -6.73% | +43.57% | +27.39% | 20.12B | |
| -0.51% | +11.45% | +147.14% | +105.09% | 19.67B | |
| +5.29% | +2.97% | +28.01% | -75.95% | 16.5B | |
| -0.73% | +2.98% | +25.96% | +66.71% | 15.76B | |
| Average | +0.54% | +1.16% | +62.24% | +78.18% | 35.72B | |
| Weighted average by Cap. | +0.88% | -0.10% | +37.81% | +60.14% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 5.92B 6.7B 857M 722M 659M 629M 1.17B 77.66B 1.21B 7.66B 3.04B 37.5B 3.22B 3.15B 131B | 6.34B 7.17B 917M 773M 705M 673M 1.25B 83.06B 1.3B 8.2B 3.25B 40.11B 3.44B 3.37B 140B |
| Net income | 896M 1.01B 130M 109M 99.64M 95.13M 177M 11.74B 183M 1.16B 460M 5.67B 486M 476M 19.82B | 702M 794M 102M 85.62M 78.1M 74.56M 138M 9.2B 144M 908M 361M 4.44B 381M 373M 15.53B |
| Net Debt | 3.14B 3.55B 455M 383M 349M 334M 619M 41.18B 643M 4.06B 1.61B 19.89B 1.7B 1.67B 69.5B | 529M 598M 76.52M 64.47M 58.8M 56.14M 104M 6.93B 108M 684M 272M 3.35B 287M 281M 11.7B |
Employees
3,537
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-02-13 | 70.35 $ | -2.22% | 885,500 |
| 26-02-12 | 71.95 $ | +0.84% | 793,276 |
| 26-02-11 | 71.35 $ | -0.83% | 5,542,800 |
| 26-02-10 | 71.95 $ | +7.31% | 6,835,244 |
| 26-02-09 | 67.05 $ | +5.09% | 910,412 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
62.17CNY
Average target price
92.97CNY
Spread / Average Target
+49.54%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 2696 Stock
Select your edition
All financial news and data tailored to specific country editions
